Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study
Antibiotics are preferentially delivered via the peritoneal route to treat peritonitis, a major complication of peritoneal dialysis (PD), so that maximal concentrations are delivered at the site of infection. However, drugs administered intraperitoneally can be absorbed into the systemic circulation.
Drugs excreted by the kidneys accumulate in PD patients, increasing the risk of toxicity. The aim of this study is to examine a model of gentamicin pharmacokinetics and to develop an intraperitoneal drug dosing regime that maximises bacterial killing and minimises toxicity.
Methods: This is an observational pharmacokinetic study of consecutive PD patients presenting to the Royal Brisbane and Women's Hospital with PD peritonitis and who meet the inclusion criteria.
Participants will be allocated to either group 1, if anuric as defined by urine output less than 100ml/day, or group 2: if non-anuric, as defined by urine output more than 100ml/day. Recruitment will be limited to 15 participants in each group.
Gentamicin dosing will be based on the present Royal Brisbane &Women's Hospital guidelines, which reflect the current International Society for Peritoneal Dialysis Peritonitis TreatmentRecommendations. The primary endpoint is to describe the pharmacokinetics of gentamicin administered intraperitoneally in PD patients with peritonitis based on serial blood and dialysate drug levels.DiscussionThe study will develop improved dosing recommendations for intraperitoneally administered gentamicin in PD patients with peritonitis.
This will guide clinicians and pharmacists in selecting the most appropriate dosing regime of intraperitoneal gentamicin to treat peritonitis.Trial RegistrationACTRN12609000446268
Author: Dwarakanathan RanganathanJulie VargheseRobert FassettJeffrey LipmanVincent D'IntiniHelen HealyJason Roberts
Credits/Source: BMC Nephrology 2009, 10:42
Published on: 2009-12-16
Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please
make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.
Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
|
|
